Showing 111-120 of 145 results for "".
- FDA Approves Janssen's Tremfya for Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-for-moderate-to-severe-plaque-psoriasis/2458123/The FDA has approved Janssen's Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a key r…
- Apax Partners To Acquire Syneron for Close to $400 millionhttps://practicaldermatology.com/news/apax-partners-to-acquire-syneron-for-close-to-400-million/2458230/An affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million. The per share acquisition price represents a 15 percent premium to Syneron Candela's 90-day volume-weight…
- Topix Pharmaceuticals Rolls Out Replenix RetinolForte Treatment Serumhttps://practicaldermatology.com/news/topix-pharmaceuticals-rolls-out-replenix-retinolforte-treatment-serum/2458242/Topix Pharmaceuticals is adding Replenix® RetinolForte Treatment Serum to their portfolio of offerings. The serum’s patent-pending, time-released Micropolymer delivery system deposits retinol into the skin so patients get the full dosage without the irritation commonly associated with a retinoid. …
- No Biopsy Required? Non-Invasive Skin Cancer Test May Offer Quick Diagnosishttps://practicaldermatology.com/news/no-biopsy-required-non-invasive-skin-cancer-test-may-offer-quick-diagnosis/2458284/A new non-invasive imaging technique may accurately detect skin cancer without surgical biopsy. Multiphoton microscopy of mitochondria accurately identified melanomas and basal cell carcinomas by detecting abnormal clusters of mitochondria in both types of skin cancer, according to researchers fun…
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Administration has cleared the company's investigat…
- Can IL-33 Blockade Ease Severe Poison Ivy Itch? Mouse Study Says Maybehttps://practicaldermatology.com/news/can-il-33-blockers-ease-severe-poison-ivy-itch/2458382/Blocking interleukin 33 (IL-33) may put the brakes on the uncontrollable itch caused by poison ivy, poison sumac, poison oak and even mango trees, according to a mouse study conducted by scientists at Duke Health in Durham, NC, and Zhejiang Chinese Medical University in China. The research appear…
- FDA OKS Santalis' Phase 2 Study of EISO For ADhttps://practicaldermatology.com/news/fda-oks-santalis-phase-2-study-of-eiso-in-ad/2458385/The U.S. Food and Drug Administration (FDA) has green lighted Santalis Pharmaceuticals Phase 2 clinical study of East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability study for th…
- Topix Pharmaceuticals Introduces All-Trans-Retinol Smoothing Body Lotionhttps://practicaldermatology.com/news/topix-pharmaceuticals-introduces-all-trans-retinol-smoothing-body-lotion/2458439/Topix Pharmaceuticals, Inc. has introduced All-trans-Retinol Smoothing Body Lotion, a retinol body treatment featuring layered ingredient technologies and a powerful delivery system for ultimate penetration. Replenix Smoothing Body Lotion contains the maximum dosage of retinol to be safe and effect…
- Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Ultra-Short 785nm Wavelengthhttps://practicaldermatology.com/news/syneron-candelas-picoway-picosecond-laser-receives-us-fda-clearance-for-ultra-short-785nm-wavelength/2458489/And then there were three. The U.S. Food and Drug Administration (FDA) has cleared Syneron Medical Ltd.’s PicoWay® picosecond laser for a new ultra-short 785nm wavelength. The addition of the new wavelength expands the capabilities of the PicoWay picosecond laser, making it possible to remove all…
- FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-advisory-arm-recommends-brodalumab-for-moderate-to-severe-plaque-psoriasis/2458497/A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committee voted 18 to 0 in favor of brodalumab injection, 210 mg, for adults with moderate-to-severe plaque psorias…